The Charcot-Marie-Tooth Association (CMTA), in collaboration with Actio Biosciences (Actio Bio), hosted a virtual patient focus group for individuals diagnosed with Charcot-Marie-Tooth disease Type 2C (CMT2C), also known as TRPV4 Neuropathy.
Engaging volunteer experts from the CMT2C patient community, the patient focus group meeting centered around capturing the CMT2C patient journey, identifying existing unmet needs, and gathering valuable insights on future treatment goals.
Moderated by CMTA, patient participants were given a platform to directly share their experiences in a manner that will contribute towards new advancements in research and the development of new potential treatments for CMT2C. Focus group participants were asked to complete a secure digital survey prior to the meeting. A combination of the survey responses submitted and verbal responses captured during the focus group meeting are presented in this report.
Published On: October 22, 2024